Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20170202xex99_2.htm |
EX-5.1 - EX-5.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20170202xex5_1.htm |
8-K - 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20170202x8k.htm |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Balance Sheets
(unaudited)
|
|||||
|
December 31, |
||||
(in thousands, except per share amounts) |
2016 |
2015 |
|||
Assets |
|||||
Current assets |
|||||
Cash and cash equivalents |
$ |
16,765 |
$ |
33,629 | |
Investments |
55,213 | 48,641 | |||
Accounts receivable |
11,421 | 5,245 | |||
Inventory |
15,634 | 10,955 | |||
Prepaid expenses and other current assets |
9,978 | 12,071 | |||
Total current assets |
109,011 | 110,541 | |||
Property and equipment, net |
14,560 | 8,548 | |||
Long-term restricted cash |
4,500 | 4,500 | |||
Other long-term assets |
9,813 | 7,518 | |||
Total assets |
$ |
137,884 |
$ |
131,107 | |
Liabilities and Stockholders’ Equity |
|||||
Current liabilities |
|||||
Accounts payable |
$ |
8,359 |
$ |
4,749 | |
Accrued expenses |
16,604 | 15,551 | |||
Deferred service revenue, current |
7,130 | 6,815 | |||
Deferred contractual revenue, current |
— |
10,822 | |||
Other liabilities, current |
1,681 | 241 | |||
Total current liabilities |
33,774 | 38,178 | |||
Deferred service revenue, non-current |
1,297 | 1,143 | |||
Deferred contractual revenue, non-current |
— |
1,312 | |||
Other liabilities, non-current |
1,683 | 1,386 | |||
Notes payable |
16,106 | 14,948 | |||
Financing derivative |
356 | 600 | |||
Total liabilities |
53,216 | 57,567 | |||
|
|||||
Commitments and contingencies |
|||||
|
|||||
Stockholders’ equity |
|||||
Preferred Stock, $0.001 par value: |
|||||
Authorized 50,000 shares; No shares issued or outstanding |
— |
— |
|||
Common Stock, $0.001 par value: |
|||||
Authorized 1,000,000 shares; Issued and outstanding 92,677 and 79,983 shares at December 31, 2016 and 2015, respectively |
93 | 80 | |||
Additional paid-in-capital |
872,114 | 786,636 | |||
Accumulated other comprehensive income (loss) |
5 | (7) | |||
Accumulated deficit |
(787,544) | (713,169) | |||
Total stockholders’ equity |
84,668 | 73,540 | |||
Total liabilities and stockholders’ equity |
$ |
137,884 |
$ |
131,107 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
|
||||||||
|
Years ended December 31, |
|||||||
(in thousands, except per share amounts) |
2016 |
2015 |
2014 |
|||||
Revenue: |
||||||||
Product revenue |
$ |
64,609 |
$ |
37,502 |
$ |
35,299 | ||
Service and other revenue |
13,971 | 10,896 | 8,511 | |||||
Contractual revenue |
12,134 | 44,384 | 16,784 | |||||
Total revenue |
90,714 | 92,782 | 60,594 | |||||
Cost of Revenue: |
||||||||
Cost of product revenue |
34,512 | 30,704 | 29,626 | |||||
Cost of service and other revenue |
12,042 | 8,628 | 7,566 | |||||
Total cost of revenue |
46,554 | 39,332 | 37,192 | |||||
Gross profit |
44,160 | 53,450 | 23,402 | |||||
Operating Expense: |
||||||||
Research and development |
67,617 | 60,440 | 48,230 | |||||
Sales, general and administrative |
47,787 | 45,187 | 38,026 | |||||
Gain on lease amendments |
— |
(23,043) |
— |
|||||
Total operating expense |
115,404 | 82,584 | 86,256 | |||||
Operating loss |
(71,244) | (29,134) | (62,854) | |||||
Interest expense |
(3,234) | (2,926) | (2,828) | |||||
Other income (expense), net |
103 | 364 | (478) | |||||
Net loss |
(74,375) | (31,696) | (66,160) | |||||
Other comprehensive loss: |
||||||||
Unrealized gain (loss) on investments |
12 | (16) | (5) | |||||
Comprehensive loss |
$ |
(74,363) |
$ |
(31,712) |
$ |
(66,165) | ||
Net loss per share: |
||||||||
Basic and diluted net loss per share |
$ |
(0.83) |
$ |
(0.42) |
$ |
(0.94) | ||
Shares used in computing basic and diluted net loss per share |
89,148 | 75,614 | 70,475 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Statements of Cash Flows
(unaudited)
|
||||||||
|
Years Ended December 31, |
|||||||
(in thousands) |
2016 |
2015 |
2014 |
|||||
Cash flows from operating activities |
||||||||
Net loss |
$ |
(74,375) |
$ |
(31,696) |
$ |
(66,160) | ||
Adjustments to reconcile net loss to net cash used in operating activities |
||||||||
Depreciation and amortization |
3,875 | 3,677 | 4,221 | |||||
Amortization of debt discount and financing costs |
1,158 | 957 | 793 | |||||
Stock-based compensation |
19,562 | 13,840 | 9,943 | |||||
Non-cash portion of gain on lease amendments |
— |
(3,043) |
— |
|||||
Other items |
(147) | (230) | 507 | |||||
Changes in assets and liabilities |
||||||||
Accounts receivable |
(6,176) | (1,738) | (660) | |||||
Inventory |
(6,151) | (2,466) | (1,285) | |||||
Prepaid expenses and other assets |
(202) | (17,889) | (224) | |||||
Accounts payable |
3,402 | (716) | 3,891 | |||||
Accrued expenses |
1,053 | 5,732 | 3,536 | |||||
Deferred service revenue |
469 | 708 | 2,686 | |||||
Deferred contractual revenue |
(12,134) | (14,386) | (6,784) | |||||
Other liabilities |
1,737 | (639) | (1,932) | |||||
Net cash used in operating activities |
(67,929) | (47,889) | (51,468) | |||||
Cash flows from investing activities |
||||||||
Purchase of property and equipment |
(8,207) | (3,009) | (1,609) | |||||
Proceeds from disposal of property and equipment |
10 | 36 |
— |
|||||
Long-term restricted cash |
— |
(4,500) |
— |
|||||
Purchase of investments |
(95,848) | (84,579) | (126,413) | |||||
Sales of investments |
23,285 | 8,317 |
— |
|||||
Maturities of investments |
65,896 | 92,341 | 147,586 | |||||
Net cash provided by (used in) investing activities |
(14,864) | 8,606 | 19,564 | |||||
Cash flows from financing activities |
||||||||
Proceeds from issuance of common stock from equity plans |
7,729 | 7,363 | 3,968 | |||||
Proceeds from issuance of common stock from "at-the-market" offering, net of issuance costs |
58,200 | 29,100 | 38,023 | |||||
Net cash provided by financing activities |
65,929 | 36,463 | 41,991 | |||||
Net increase (decrease) in cash and cash equivalents |
(16,864) | (2,820) | 10,087 | |||||
Cash and cash equivalents at beginning of period |
33,629 | 36,449 | 26,362 | |||||
Cash and cash equivalents at end of period |
$ |
16,765 |
$ |
33,629 |
$ |
36,449 | ||
|
||||||||
Supplemental disclosure of cash flow information |
||||||||
Interest paid |
$ |
1,799 |
$ |
1,794 |
$ |
1,794 | ||
|
||||||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Inventory transferred to property and equipment |
1,282 | 2,846 |
— |
|||||
|